临床试验中的粒细胞集落刺激因子和粒细胞-巨噬细胞集落刺激因子。
G-CSF and GM-CSF in clinical trials.
作者信息
Antman K H
机构信息
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
出版信息
Yale J Biol Med. 1990 Sep-Oct;63(5):387-410.
Hematopoietic growth factors have now been purified, cloned, and produced in bacteria and yeast. Those that are currently in clinical study include erythropoietin, GM-CSF, G-CSF, M-CSF (also called CSF-1), and multi-CSF (also called interleukin 3). Growth factor appear likely to enhance the recovery and function of circulating white cells after standard-dose cancer therapy and high-bone-dose cancer therapy with marrow transplant and to restore leukocyte numbers and competence in the acquired immune deficiency syndromes and myelodysplastic syndromes. Phase I, II trials in AIDS, in cancer patients receiving chemotherapy, in cases of myeloproliferative disease, and after bone marrow transplant have been published. The results of phase III studies are just becoming available.
造血生长因子现已被纯化、克隆，并在细菌和酵母中生产。目前正在进行临床研究的有促红细胞生成素、粒细胞-巨噬细胞集落刺激因子、粒细胞集落刺激因子、巨噬细胞集落刺激因子（也称为集落刺激因子-1）和多集落刺激因子（也称为白细胞介素3）。生长因子似乎有可能增强标准剂量癌症治疗以及骨髓移植高剂量癌症治疗后循环白细胞的恢复和功能，并恢复获得性免疫缺陷综合征和骨髓增生异常综合征患者的白细胞数量和功能。关于艾滋病患者、接受化疗的癌症患者、骨髓增殖性疾病患者以及骨髓移植后的一期和二期试验已经发表。三期研究的结果刚刚公布。
Zotero 插件